Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

计划入组 108 人 · 首次发布于 2025 年 1 月 22 日

CAREMM-2306: Advanced Immunotherapy vs. Classical Immunotherapy

计划入组 2,500 人 · 首次发布于 2024 年 1 月 12 日

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

计划入组 48 人 · 首次发布于 2025 年 10 月 3 日

ATTO-003

ATTO-004

ATTO-005

ALTO NEUROSCIENCE, INC.

United States

PALO ALTO UNIVERSITY

United States

LI AUTO-W

Canada

Attovia Therapeutics Raises $289M in Upsized IPO to Advance Biparatopic Nanobody Pipeline in Immunology

Attovia Therapeutics Initiates Phase 1 Trial of Novel Anti-IL-31 Therapy for Chronic Pruritus

Ten Adalimumab Biosimilars Now Available in US Market Following Latest FDA Approval